4.5 Article

High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue Inhibitor

Journal

ACS MEDICINAL CHEMISTRY LETTERS
Volume 10, Issue 5, Pages 708-713

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.9b00002

Keywords

Aminopeptidase; enzyme; inhibitor; structure; X-ray; mechanism; antigen; peptide; immune system

Funding

  1. Harry J. Lloyd Charitable Trust
  2. project NCSRD-INRASTES research activities in the framework of the national RIS3 under the Action for the Strategic Development on the Research and Technological Sector - Operational Programme Competitiveness, Entrepreneurship and Innovation [MIS 5002559, NSRF 2014-2020]
  3. European Union (European Regional Development Fund)
  4. project INSPIRED-The National Research Infrastructures on Integrated Structural Biology, Drug Screening Efforts and Drug Target Functional Characterization under the Action Reinforcement of the Research and Innovation Infrastructure, funded by the Oper [NSRF 2014-2020, MIS 5002550]
  5. iNEXT [5589]
  6. EMBL-Hamburg [MX-619]

Ask authors/readers for more resources

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an intra-cellular enzyme that helps generate peptides presented by Major Histocompatibility Complex Class I (MHC class I) molecules and is an emerging target for immunotherapy applications. Despite almost two decades of research on ERAP1, lack of high-resolution crystal structures has hampered drug-development efforts. By optimizing the protein construct, we obtained a high-resolution (1.60 angstrom) crystal structure of the closed-conformation of ERAP1 with a potent phosphinic pseudopeptide inhibitor bound in its active site. The structure provides key insight on the mechanism of inhibition as well as selectivity toward homologous enzymes and allows detailed mapping of the internal cavity of the enzyme that accommodates peptide-substrates. Bis-tris propane and malic acid molecules, found bound in pockets in the internal cavity, reveal potential druggable secondary binding sites. The ability to obtain high-resolution crystal structures of ERAP1 removes a major bottleneck in the development of compounds that regulate its activity and will greatly accelerate drug-discovery efforts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available